Multiple sclerosis

Basic and clinical

Katherine Buzzard, Wing Hei Chan, Trevor Kilpatrick, Simon Murray

Research output: Chapter in Book/Report/Conference proceedingChapter (Book)Otherpeer-review

Abstract

Multiple sclerosis (MS) is the most common neurodegenerative disease affecting young adults in our community. It is a complex disease influenced by gender, genetic and environmental factors. MS is a chronic inflammatory disease of the central nervous system caused by aberrant immune activation resulting in damage to myelin sheaths within the brain and spinal cord and axonal loss. The demyelinating insult initially impairs the speed and efficiency of nerve cell function. In the majority of cases, this is followed by an innate endogenous repair response that can restore the myelin sheath and nerve cell function to relatively normal levels. However over time and with subsequent demyelinating events, this capacity is lost ultimately leading to neural degeneration. The influences that oligodendrocytes and myelin exert upon nerve cells to sustain their health and viability have begun to be identified. While immune-directed therapies can reduce the frequency of relapses and development of new lesions, they have little effect upon remyelination and nerve cell repair. This presents the next big challenge in MS therapeutics; complementing immune targeted therapies with strategies that directly target the primary cause of disability, that of remyelination.

Original languageEnglish
Title of host publicationNeurodegenerative Diseases
Subtitle of host publicationPathology, Mechanisms, and Potential Therapeutic Targets
EditorsPhilip Beart, Michael Robinson, Marcus Rattray, Nicholas J. Maragakis
PublisherSpringer
Chapter8
Pages211-252
Number of pages42
ISBN (Print)9783319571911, 9783319571935
DOIs
Publication statusPublished - 2017
Externally publishedYes

Publication series

NameAdvances in Neurobiology
Volume15
ISSN (Print)2190-5215

Keywords

  • Demyelination
  • Multiple sclerosis
  • Myelin
  • Oligodendrocyte
  • Remyelination

Cite this

Buzzard, K., Chan, W. H., Kilpatrick, T., & Murray, S. (2017). Multiple sclerosis: Basic and clinical. In P. Beart, M. Robinson, M. Rattray, & N. J. Maragakis (Eds.), Neurodegenerative Diseases: Pathology, Mechanisms, and Potential Therapeutic Targets (pp. 211-252). (Advances in Neurobiology; Vol. 15). Springer. https://doi.org/10.1007/978-3-319-57193-5_8
Buzzard, Katherine ; Chan, Wing Hei ; Kilpatrick, Trevor ; Murray, Simon. / Multiple sclerosis : Basic and clinical. Neurodegenerative Diseases: Pathology, Mechanisms, and Potential Therapeutic Targets. editor / Philip Beart ; Michael Robinson ; Marcus Rattray ; Nicholas J. Maragakis. Springer, 2017. pp. 211-252 (Advances in Neurobiology).
@inbook{312195f7593d46f3883766f4638341f3,
title = "Multiple sclerosis: Basic and clinical",
abstract = "Multiple sclerosis (MS) is the most common neurodegenerative disease affecting young adults in our community. It is a complex disease influenced by gender, genetic and environmental factors. MS is a chronic inflammatory disease of the central nervous system caused by aberrant immune activation resulting in damage to myelin sheaths within the brain and spinal cord and axonal loss. The demyelinating insult initially impairs the speed and efficiency of nerve cell function. In the majority of cases, this is followed by an innate endogenous repair response that can restore the myelin sheath and nerve cell function to relatively normal levels. However over time and with subsequent demyelinating events, this capacity is lost ultimately leading to neural degeneration. The influences that oligodendrocytes and myelin exert upon nerve cells to sustain their health and viability have begun to be identified. While immune-directed therapies can reduce the frequency of relapses and development of new lesions, they have little effect upon remyelination and nerve cell repair. This presents the next big challenge in MS therapeutics; complementing immune targeted therapies with strategies that directly target the primary cause of disability, that of remyelination.",
keywords = "Demyelination, Multiple sclerosis, Myelin, Oligodendrocyte, Remyelination",
author = "Katherine Buzzard and Chan, {Wing Hei} and Trevor Kilpatrick and Simon Murray",
year = "2017",
doi = "10.1007/978-3-319-57193-5_8",
language = "English",
isbn = "9783319571911",
series = "Advances in Neurobiology",
publisher = "Springer",
pages = "211--252",
editor = "Philip Beart and Michael Robinson and Marcus Rattray and Maragakis, {Nicholas J. }",
booktitle = "Neurodegenerative Diseases",

}

Buzzard, K, Chan, WH, Kilpatrick, T & Murray, S 2017, Multiple sclerosis: Basic and clinical. in P Beart, M Robinson, M Rattray & NJ Maragakis (eds), Neurodegenerative Diseases: Pathology, Mechanisms, and Potential Therapeutic Targets. Advances in Neurobiology, vol. 15, Springer, pp. 211-252. https://doi.org/10.1007/978-3-319-57193-5_8

Multiple sclerosis : Basic and clinical. / Buzzard, Katherine; Chan, Wing Hei; Kilpatrick, Trevor; Murray, Simon.

Neurodegenerative Diseases: Pathology, Mechanisms, and Potential Therapeutic Targets. ed. / Philip Beart; Michael Robinson; Marcus Rattray; Nicholas J. Maragakis. Springer, 2017. p. 211-252 (Advances in Neurobiology; Vol. 15).

Research output: Chapter in Book/Report/Conference proceedingChapter (Book)Otherpeer-review

TY - CHAP

T1 - Multiple sclerosis

T2 - Basic and clinical

AU - Buzzard, Katherine

AU - Chan, Wing Hei

AU - Kilpatrick, Trevor

AU - Murray, Simon

PY - 2017

Y1 - 2017

N2 - Multiple sclerosis (MS) is the most common neurodegenerative disease affecting young adults in our community. It is a complex disease influenced by gender, genetic and environmental factors. MS is a chronic inflammatory disease of the central nervous system caused by aberrant immune activation resulting in damage to myelin sheaths within the brain and spinal cord and axonal loss. The demyelinating insult initially impairs the speed and efficiency of nerve cell function. In the majority of cases, this is followed by an innate endogenous repair response that can restore the myelin sheath and nerve cell function to relatively normal levels. However over time and with subsequent demyelinating events, this capacity is lost ultimately leading to neural degeneration. The influences that oligodendrocytes and myelin exert upon nerve cells to sustain their health and viability have begun to be identified. While immune-directed therapies can reduce the frequency of relapses and development of new lesions, they have little effect upon remyelination and nerve cell repair. This presents the next big challenge in MS therapeutics; complementing immune targeted therapies with strategies that directly target the primary cause of disability, that of remyelination.

AB - Multiple sclerosis (MS) is the most common neurodegenerative disease affecting young adults in our community. It is a complex disease influenced by gender, genetic and environmental factors. MS is a chronic inflammatory disease of the central nervous system caused by aberrant immune activation resulting in damage to myelin sheaths within the brain and spinal cord and axonal loss. The demyelinating insult initially impairs the speed and efficiency of nerve cell function. In the majority of cases, this is followed by an innate endogenous repair response that can restore the myelin sheath and nerve cell function to relatively normal levels. However over time and with subsequent demyelinating events, this capacity is lost ultimately leading to neural degeneration. The influences that oligodendrocytes and myelin exert upon nerve cells to sustain their health and viability have begun to be identified. While immune-directed therapies can reduce the frequency of relapses and development of new lesions, they have little effect upon remyelination and nerve cell repair. This presents the next big challenge in MS therapeutics; complementing immune targeted therapies with strategies that directly target the primary cause of disability, that of remyelination.

KW - Demyelination

KW - Multiple sclerosis

KW - Myelin

KW - Oligodendrocyte

KW - Remyelination

UR - http://www.scopus.com/inward/record.url?scp=85022067922&partnerID=8YFLogxK

U2 - 10.1007/978-3-319-57193-5_8

DO - 10.1007/978-3-319-57193-5_8

M3 - Chapter (Book)

SN - 9783319571911

SN - 9783319571935

T3 - Advances in Neurobiology

SP - 211

EP - 252

BT - Neurodegenerative Diseases

A2 - Beart, Philip

A2 - Robinson, Michael

A2 - Rattray, Marcus

A2 - Maragakis, Nicholas J.

PB - Springer

ER -

Buzzard K, Chan WH, Kilpatrick T, Murray S. Multiple sclerosis: Basic and clinical. In Beart P, Robinson M, Rattray M, Maragakis NJ, editors, Neurodegenerative Diseases: Pathology, Mechanisms, and Potential Therapeutic Targets. Springer. 2017. p. 211-252. (Advances in Neurobiology). https://doi.org/10.1007/978-3-319-57193-5_8